SUMMARY
Jian L. Campian, M.D., Ph.D., is a medical neuro-oncologist with a long-standing interest in developing novel immunotherapeutic approaches to treat brain tumors. She is the principal investigator or co-investigator for numerous clinical trials on primary brain tumors and metastatic brain tumors. Dr. Campian has led pioneering translational and clinical research to boost innate immunity and promote immune reconstitution.
She also is a pioneer in applying chronotherapy-based interventions in cancer. As a translational and clinical physician-scientist, Dr. Campian has been active and successful in developing and executing multiple investigator-initiated early-phase clinical trials in central nervous system cancers. In addition, Dr. Campian has a special interest in clinical trial conduct in cancer research and innovative trial designs in neuro-oncology.
Focus areas
- Mitigating treatment-related immune suppression. Dr. Campian leads two multicenter investigator-initiated trials to test novel cytokine therapies to boost T lymphocyte numbers and function in patients with brain tumors.
- Improving drug delivery and augmenting immune therapy. Dr. Campian conducted two investigator-initiated trials to study a novel approach combining laser interstitial thermal therapy (LITT) with immune checkpoint inhibitor therapy or chemotherapy to treat brain tumors.
- Overcoming immune-suppressive tumor microenvironment. Dr. Campian is leading a multicenter investigator-initiated study to evaluate the synergetic effects of targeting indoleamine 2, 3-dioxygenase 1 (IDO1), an immune suppressor, in the tumor microenvironment, and programmed cell death protein 1 (PD-1), along with hypofractionated radiotherapy in recurrent glioblastoma.
- Optimizing chemotherapy using circadian medicine and chronotherapeutic approaches. Dr. Campian and her collaborators are the first group to study chronomedicine of oral chemotherapies in patients in the United States and around the world. Dr. Campian also conducted an investigator-initiated trial to study chronotherapy of the oral alkylating agent temozolomide in patients with glioblastoma.
Significance to patient care
Dr. Campian's long-term research goal is to successfully treat solid tumors with cytokine and other immunotherapeutic approaches. She also hopes to develop novel therapeutic approaches to treat gliomas, with a special focus on individualized treatment and correcting treatment-related lymphopenia.
Professional highlights
- Associate medical director, Cancer Clinical Trials Office, Mayo Clinic Comprehensive Cancer Center, 2022-present.
- Associate editor, Frontiers in Oncology, 2022-present.
- Castle Connolly Top Doctor, 2021.
- Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine:
- Associate director, Brain Tumor Center, 2019-2021.
- Advisor, Quality Assurance and Safety Monitoring Committee, 2017-2021.
- Clinical director, Neuro-Oncology Program, Division of Oncology, 2015-2021.
- Co-leader, Neuro-Oncology Focus Group, 2014-2021.
- Best Doctors in America, 2019-2021.
- Voting panel member, Central Nervous System Cancers and Brain Metastasis, National Comprehensive Cancer Network, 2019-2021.